This trial studies the side effects and best dose of two drugs, trametinib and everolimus, in treating pediatric and young adult patients with low grade gliomas that has come back (recurrent).
- Brain Tumor
- WHO Grade II Glioma
- Low Grade Glioma
6 Primary · 0 Secondary · Reporting Duration: Up to 5 years
Side Effects for
1 Treatment Group
Treatment (trametinib, everolimus)
1 of 1
50 Total Participants · 1 Treatment Group
Primary Treatment: Trametinib · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 1 - 25 · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What potential dangers do individuals face when using Trametinib?
"Trametinib's safety is rated as a 1 since this trial falls under Phase 1, indicating that only minimal evidence exists to support its effectiveness and security." - Anonymous Online Contributor
Are there any eligibility requirements I must meet to be accepted into this clinical trial?
"This medical trial is recruiting 50 individuals with glioma between one year old and 25 years. The criteria to join the study necessitate that participants must have a histologically confirmed diagnosis of LGG (WHO grade I-II) or HGG (WHO Grade III-VI). Moreover, patients need to have received prior therapy other than surgery, such as chemotherapy, biologics, immunotherapy or radiotherapy before enrolling in this research project. Also required are snap frozen tissue samples for comprehensive genomic testing or results from similar tests previously conducted. Additionally those who had taken myelosuppressive anticancer drugs should've ceased their intake three" - Anonymous Online Contributor
How many individuals are partaking in this research endeavor?
"This clinical research is in search of 50 eligible patients, who are able to adhere to the inclusion criteria. Those interested may take part from medical centers such as University of Florida in Gainesville and Riley Hospital for Children in Indianapolis." - Anonymous Online Contributor
Does this research endeavor cater to individuals aged 85 and over?
"This medical trial mandates that participants must be between a year old and 25 years of age. 285 studies are available for minors while 1,270 can provide assistance to elderly individuals." - Anonymous Online Contributor
What pathologies is Trametinib commonly administered to address?
"Trametinib is a medication capable of treating unresectable melanoma, liver transplant rejection and renal allotransplant rejections." - Anonymous Online Contributor
Is this research being conducted in numerous hospitals across the North American region?
"The study is currently enrolling patients at University of Florida (Gainesville, FL), Riley Hospital for Children (Indianapolis, IN) and University of California San Francisco (San Francisco, CA). Additionally, there are 14 other medical centres included in the trial." - Anonymous Online Contributor
Are recruits welcome to join this experiment?
"Clinicaltrials.gov confirms that this medical research is still recruiting patients, having been first posted on December 9th 2020 and updated most recently on October 28th 2022." - Anonymous Online Contributor
Could you please summarize any prior research related to Trametinib?
"Trametinib was initially studied at Sheba Medical Center in 2008. Since then, 472 trials have been completed with 180 more actively recruiting clinical participants. The majority of these new studies are conducted out of Gainesville, Florida." - Anonymous Online Contributor